Zydus Cadila seeks approval for 'breakthrough' Covid drug
Zydus Cadila announced that its Phase III clinical trials with Pegylated Interferon Alpha 2b has shown promising results in treating COVID-19.
Zydus Cadila announced that its Phase III clinical trials with Pegylated Interferon Alpha 2b has shown promising results in treating COVID-19.
0 Comments
Post a Comment